Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Sept. 15 — In separate warning letters posted online Sept. 15, the FDA told Jaychem Industries Ltd. and Pan Drugs Ltd. that the agency's inspections revealed they hadn't complied with current good manufacturing practices (cGMPs).
The Food and Drug Administration said that as a result of the inspections, drug products made by the companies were considered “adulterated” under the Federal Food, Drug, and Cosmetic Act.
In a letter to Jaychem dated Sept. 4, the FDA said it found violations at an Auckland, New Zealand, facility during an inspection that ended July 10, 2014.
The FDA said Jaychem failed to ensure the quality of components, including active pharmaceutical ingredients from various suppliers. The agency also said the firm failed to establish written control procedures and failed to test finished drug batches for the identity and strength of active ingredients.
Additionally, the FDA said that Jaychem has no data to demonstrate that the chemical and physical properties of a certain product (name of the product was redacted) remain acceptable throughout its shelf life.
In a letter to Pan Drugs dated Sept. 2, the FDA said it found violations at its Vadodara, India, facility during an inspection that ended July 18, 2014.
The FDA said the company failed to properly maintain, repair and keep clean buildings used in the manufacture of active pharmaceutical ingredients (APIs) in a manner that prevents contamination. For example, the agency said its investigator observed holes in the walls and roof, which allowed pigeons access near production equipment in multiple manufacturing areas.
The agency also said Pan Drugs failed to properly maintain equipment used in the manufacture of APIs. The letter said the FDA investigator observed rust, dirt, lubrication leaks and exposed insulation material on and around open drug manufacturing equipment.
In addition, the company failed to maintain complete data derived from all testing and to ensure conformance with established specifications and standards.
The FDA told both companies that they should hire a third-party consultant with appropriate cGMP expertise to comprehensively assess the facilities.
The agency also told both companies that until they complete all corrections, the FDA may withhold approval of any new applications or supplements listing the companies as drug product manufacturers.
The FDA told Pan Drugs that until it receives adequate confirmation that the company has made global corrections, it will not schedule a follow-up inspection and the company will remain on an import alert, meaning that any drug products manufactured by the facility would be refused admission into the U.S.
Both companies were asked to provide a response to the warning letters. The letters were signed by Thomas J. Cosgrove, director of the FDA's Office of Manufacturing Quality.
The letter to Jaychem is at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2015/ucm462371.htm and the letter to Pan Drugs is at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2015/ucm462075.htm.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)